Statins in MASLD: Frontiers in Pharmacology | July 2026

Introduction:

Statins are routinely prescribed in metabolic dysfunction-associated steatotic liver disease (MASLD) to reduce cardiovascular risk, but emerging evidence suggests their benefits may extend directly to the liver. This translational review explores how statins may influence hepatic inflammation, fibrosis, sinusoidal dysfunction, and hepatocarcinogenesis through mechanisms largely independent of LDL-cholesterol reduction.

Why was this review needed?

Cardiovascular disease remains a major cause of mortality in MASLD.

Statins remain underused because of persistent concerns regarding liver safety.

Experimental and observational evidence suggests potential hepatoprotective effects beyond lipid-lowering.

Understanding these mechanisms could clarify the future role of statins across the MASLD spectrum.

Key Takeaways:

Statins inhibit the mevalonate pathway, reducing FPP/GGPP and thereby limiting prenylation of Ras, Rho, Rac, and Cdc42—a potential central mechanism behind their hepatic effects.

This may reduce lipotoxicity, NLRP3-mediated inflammation, and hepatic stellate-cell activation, providing biological plausibility for antifibrotic effects.

Statins may improve sinusoidal endothelial function through KLF2/eNOS signaling, potentially reducing intrahepatic vascular resistance.

Modulation of Ras/Rho and YAP/TAZ signaling may also contribute to the observed association between statin exposure and lower HCC risk.

Human observational studies suggest associations with slower fibrosis progression, fewer decompensation events, and reduced HCC risk, but dedicated randomized trials are lacking.

Potential liver benefit appears most plausible in pre-cirrhotic MASLD and compensated cirrhosis; benefit has not been established in decompensated disease.

Clinical Impact:

MASLD should not be considered a reason to withhold an otherwise indicated statin, including in patients with mild aminotransferase elevation. The evolving concept is that statins may provide a dual cardiovascular and hepatic benefit. However, current evidence does not justify prescribing statins solely as MASH-directed or antifibrotic therapy.

Bottom Line:

In MASLD, statins should be viewed as more than LDL-lowering drugs: their effects on the mevalonate–prenylation pathway may favorably influence inflammation, fibrosis, portal hemodynamics, and carcinogenesis. For now, treat appropriate cardiovascular indications confidently—the possibility of genuine liver-modifying benefit is promising but awaits dedicated randomized trials.